Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013

Published: Monday, November 12, 2012
Last Updated: Sunday, November 11, 2012
Bookmark and Share
Company prepared for pivotal trials with CYT387 during the quarter.

YM BioSciences Inc. has reported operational and financial results for the first quarter of fiscal 2013, ended September 30, 2012.

"During the quarter we prepared for pivotal trials with CYT387 while continuing to explore potential opportunities to further develop and/or commercialize our drug with other companies," said Dr. Nick Glover, President and CEO of YM BioSciences.

Dr. Glover continued, "We look forward to reporting final results from the 166 patient Phase I/II study of CYT387 in myelofibrosis, which have been selected for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology."

Summary Financial Results (CDN dollars)
The interim consolidated financial statements and comparative information for fiscal 2013 have been prepared in accordance with International Financial Reporting Standards ("IFRS").

Revenue, generated from out-licensing remained constant for the first quarter of fiscal 2013 ending September 30, 2012 at $0.3 million compared with $0.3 million for the first quarter of fiscal 2012 ending September 30, 2011.

Net finance income was $0.4 million for the first quarter of fiscal 2013 compared to net finance income of $7.5 million for the first quarter of fiscal 2012. The changes in net finance income are primarily attributable to changes in the fair value adjustment for USD warrants.

Under IFRS, warrants denominated in a different currency than the Company's functional currency must be classified as a financial liability and measured at fair value, with changes reflected in profit or loss.

For the first quarter of fiscal 2013, the Company realized a gain of $1.7 million on the revaluation of warrants, compared to a gain of $5.4 million for the first quarter of fiscal 2012.

Licensing and product development expenses were $7.2 million for the first quarter of fiscal 2013 compared with $6.5 million for the first quarter of fiscal 2012.

Development expenses for CYT387 increased due to preparations for the Phase III program in myelofibrosis, the extension of the Phase I/II clinical trial in myelofibrosis, ongoing costs associated with the BID study, pre-clinical development activities, and manufacturing of drug for these programs.

General and administrative expenses were $2.0 million for the first quarter of fiscal 2013 compared to $2.2 million for the first quarter of fiscal 2012, primarily due to lower non-cash share-based compensation expense.

Net loss for the first quarter of fiscal 2013 was $8.5 million ($0.05 per share) compared to $0.9 million ($0.01 per share) for the same period last year.

As at September 30, 2012 the Company had cash and short-term deposits totaling $125.5 million and accounts payable and accrued liabilities totaling $5.0 million compared to $132.5 million and $3.1 million respectively as at June 30, 2012.

As at September 30, 2012 the Company had 157,546,793 common shares and 7,366,418 warrants outstanding.

Notice of Meeting:
YM's Annual Meeting of Shareholders will be held on November 20, 2012, at 4:00 p.m. ET at the offices of Norton Rose Canada LLP, Boardrooms A & B, 38th Floor, 200 Bay Street, Royal Bank Plaza South Tower, Toronto, Ontario.

The management proxy circular documents and annual financial documents were mailed to shareholders on October 8, 2012, and are available online at www.ymbiosciences.com, www.edgar.com and www.sedar.com.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 at ASH 2012
68% transfusion independence response rate and 37% durable spleen response rate.
Tuesday, December 11, 2012
YM BioSciences Announces Election of Dr. Kapil Dhingra
Dr. Dhingra has been elected by shareholders to the Company's Board of Directors.
Thursday, November 22, 2012
YM BioSciences Reports CYT387 Phase I/II Results Selected by ASH Program Committee
Phase I/II results selected for oral presentation at ASH2012 conference.
Friday, October 12, 2012
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
Pivotal trials for CYT387 in myelofibrosis to begin in the second half of calendar 2012.
Tuesday, May 15, 2012
YM BioSciences Reports Operational and Financial Results
Company reports operational and financial results for the second quarter of fiscal 2012.
Friday, February 10, 2012
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported.
Tuesday, December 13, 2011
YM BioSciences Nimotuzumab Results Reported at SIOP Conference
Phase II study of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma.
Tuesday, November 01, 2011
YM BioSciences Proposes Dr. Catherine Mackey and Dr. Nicole Onetto for Nomination to Board of Directors
Company announces annual and special meeting of shareholders and appoints new head of strategic alliances.
Monday, October 24, 2011
YM BioSciences Reports Fiscal 2011 Year End Operational and Financial Results
Enrollment of phase I/II trial for CYT387 complete.
Monday, September 26, 2011
YM BioSciences Reports Interim Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASCO
Favorable safety and durable efficacy responses recorded.
Thursday, September 01, 2011
YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387
Poster with broader update of trial results to be presented at ASCO.
Thursday, May 19, 2011
YM BioSciences Reports Fiscal Third Quarter 2011 Operational and Financial Results
Operational and financial results for the third quarter of fiscal 2011, ended March 31, 2011.
Thursday, May 12, 2011
YM BioSciences Reports Positive Updated Anemia Response Data for its JAK1/JAK2 Inhibitor CYT387
Results disclosed at First Annual Florence Meeting on Myeloproliferative Neoplasms in Florence, Italy.
Tuesday, April 19, 2011
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial
YM BioSciences Inc., a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, have announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.
Friday, January 21, 2011
YM BioSciences Reports Positive Interim Data from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Results including substantial Anemia response presented at the 52nd American Society of Hematology Annual meeting.
Tuesday, December 07, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
10X Genomics Releases Linked-Read Data from NIST Genome Samples
Genome in a Bottle Consortium data submission for webinar presentation and public availability.
Study Sheds Light on the Causes of Cerebral Palsy
Wider use of genetic testing in children with CP should be considered.
Pitt Researchers to Monitor Resistance to HIV Drugs in Africa
Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.
Environmental Epigenetics Affects Disease, Evolution
Researchers say environmental factors are having an underappreciated effect on the course of disease and evolution by prompting genetic mutations through epigenetics, a process by which genes are turned on and off independent of an organism’s DNA sequence.
Critical New Insights on DNA Repair
The enzyme fumarase is key to reversing genetic damage leading to cancer and therapy resistance.
Potential Treatment for Muscular Dystrophy
A new method for producing muscle cells could offer a better model for studying muscle diseases, such as muscular dystrophy, and for testing potential treatment options.
Nanoparticles Used to Breach Mucus Barrier in Lungs
Proof-of-concept study conducted in mice is a key step toward better treatments for lung diseases.
New Biosensors for Managing Microbial ‘Workers’
Researchers at Harvard’s Wyss Institute have unveiled new biosensors that enable scientists to more effectively control and 'communicate with' engineered bacteria.
Researchers Identify Protein in Mice that Helps Prepare for Healthy Egg-sperm Union
Protein RGS2 plays a critical role in preserving the fertilizability of the ovulated egg.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!